



GETTING STARTED WITH



INDICATION

NYVEPRIA is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count in people with certain types of cancer (non-myeloid) who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

SELECTED SAFETY INFORMATION

Do not take NYVEPRIA if you have had a serious allergic reaction to pegfilgrastim products or filgrastim products.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

WHAT YOU SHOULD KNOW WHEN STARTING NYVEPRIA

Understanding your cancer treatment plan can be overwhelming. Some plans include strong chemotherapy (chemo), which works by killing fast-growing cancer cells in your body. At the same time, chemo can lower your white blood cell count—which increases your risk of serious infection during treatment.

This guide will help you learn:



About NYVEPRIA



How NYVEPRIA can help reduce the risk of infection



How NYVEPRIA is given



What side effects can occur with NYVEPRIA treatment

SELECT SAFETY INFORMATION

Before you receive NYVEPRIA, tell your healthcare provider about all of your medical conditions, including if you:

- Have a sickle cell disorder
- Have kidney problems
- Are pregnant or plan to become pregnant. It is not known if NYVEPRIA will harm your unborn baby
- Are breastfeeding or plan to breastfeed. It is not known if NYVEPRIA passes into your breast milk

Please see Important Safety Information and Indication on pages 13-16 and [full Prescribing Information, Patient Information, and Instructions for Use](#) available at NYVEPRIA.com.


INJECTION
Nyvepria™
pegfilgrastim-apgf
The Pfizer logo, consisting of a stylized 'P' followed by the word 'Pfizer'.

ABOUT NYVEPRIA

NYVEPRIA is a biosimilar to Neulasta® (pegfilgrastim). Biosimilars are FDA-approved medicines that are highly similar to existing biologics, or reference products. Even though biosimilars are not exact copies, they are designed to have no clinically meaningful differences in safety and effectiveness from the reference product. NYVEPRIA is expected to work in the same way as Neulasta.

NYVEPRIA is a white blood cell booster that can help reduce the risk of infection during chemotherapy. Your doctor may recommend it for your first cycle through your last.

NYVEPRIA stimulates the growth of neutrophils, a type of white blood cell important in the body's fight against infection. If you are receiving NYVEPRIA because you are also receiving chemotherapy, the last dose of NYVEPRIA should be injected at least 14 days before and 24 hours after your dose of chemotherapy.



Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


TAKING NYVEPRIA

Your healthcare provider will use a prefilled syringe to administer NYVEPRIA via an injection under the skin (subcutaneous).

If your healthcare provider decides that the subcutaneous injections can be given at home by you or your caregiver, follow the detailed “Instructions for Use” that comes with your NYVEPRIA for information on how to prepare and inject a dose of NYVEPRIA.



You and your caregiver will be shown how to properly prepare and inject NYVEPRIA prior to use.



You should not inject children weighing less than 45 kg with a prefilled syringe containing NYVEPRIA. A dose less than 0.6 mL (6 mg) cannot be accurately measured using the NYVEPRIA prefilled syringe.



If you're receiving NYVEPRIA because you're also receiving chemo, the last dose of NYVEPRIA should be injected at least 14 days before and 24 hours after your dose of chemotherapy.



If you miss a dose of NYVEPRIA, talk to your healthcare provider about when you should take your next dose.

SELECT SAFETY INFORMATION

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


POSSIBLE SIDE EFFECTS OF NYVEPRIA

It is important to know the potential side effects of NYVEPRIA. Your doctor may stop treatment if any serious side effects occur.

Be sure to contact your healthcare team if there are any signs of the side effects listed below.

NYVEPRIA may cause serious side effects, including:

Spleen rupture



Your spleen may become enlarged and can rupture while taking NYVEPRIA. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the upper-left stomach area or left shoulder.

A serious lung problem called acute respiratory distress syndrome (ARDS)



Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.

Serious allergic reactions



NYVEPRIA can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have these symptoms, stop using NYVEPRIA and call your healthcare provider or get emergency medical help right away.

Additional possible side effects continued on the following pages.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at [NYVEPRIA.com](https://www.nyvepria.com).

INJECTION
Nyvepria™
pegfilgrastim-apgf


POSSIBLE SIDE EFFECTS OF NYVEPRIA (continued)



Sickle cell crises

You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive NYVEPRIA. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.



Kidney injury (glomerulonephritis)

NYVEPRIA can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:

- swelling of your face or ankles
 - blood in your urine or dark-colored urine
 - you urinate less than usual
-



Increased white blood cell count (leukocytosis)

Your healthcare provider will check your blood during treatment with NYVEPRIA.

Additional possible side effects continued on the following pages.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


POSSIBLE SIDE EFFECTS OF NYVEPRIA (continued)



Decreased platelet count (thrombocytopenia)

Your healthcare provider will check your blood during treatment with NYVEPRIA. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with NYVEPRIA. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.



Capillary Leak Syndrome

NYVEPRIA can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:

- swelling or puffiness and are urinating less than usual
- trouble breathing
- swelling of your stomach area (abdomen) and feeling of fullness
- dizziness or feeling faint
- a general feeling of tiredness

Additional possible side effects continued on the next page.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


POSSIBLE SIDE EFFECTS OF NYVEPRIA (continued)



Myelodysplastic syndrome and acute myeloid leukemia

If you have breast cancer or lung cancer, when NYVEPRIA is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with NYVEPRIA.



Inflammation of the aorta (aortitis)

Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim products. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of NYVEPRIA is pain in your bones and in your arms and legs.

These are not all the possible side effects of NYVEPRIA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at **1-800-FDA-1088**.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


WHAT FINANCIAL SUPPORT MAY BE AVAILABLE FOR MY NYVEPRIA PRESCRIPTION?

At Pfizer Oncology Together™, we treat your individual needs as a priority. We'll help you identify financial assistance options so you can get your prescribed NYVEPRIA, regardless of your insurance coverage: commercial, Medicare/government issued, or uninsured.

Eligible patients
may pay as little as

\$0

per treatment

- Pfizer Oncology Together Co-Pay Savings Program for Injectables
 - Eligible, commercially insured patients* may pay as little as \$0 per treatment for NYVEPRIA, regardless of income.† Limits, terms, and conditions apply. See page 10

FOR LIVE, PERSONALIZED SUPPORT

Call **1-877-744-5675** (Monday–Friday 8 AM–8 PM ET) or Visit **PfizerOncologyTogether.com**

*For patients to be eligible for the Injectables Co-Pay Program for NYVEPRIA, they must have commercial insurance that covers NYVEPRIA and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for NYVEPRIA benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for NYVEPRIA administered in the outpatient setting.

†The Injectables Co-Pay Program for NYVEPRIA will pay the co-pay for NYVEPRIA up to the annual assistance limit of \$10,000 per calendar year per patient.

*Please see **Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.***

INJECTION
Nyvepria™
pegfilgrastim-apgf


Terms and Conditions: By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below:

The Pfizer Oncology Together Co-Pay Savings Program for Injectables for NYVEPRIA™ is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). Program offer is not valid for cash-paying patients. With this program, eligible patients may pay as little as \$0 co-pay per NYVEPRIA treatment, subject to a maximum benefit of \$10,000 per calendar year for out-of-pocket expenses for NYVEPRIA including co-pays or coinsurances. The amount of any benefit is the difference between your co-pay and \$0. After the maximum of \$10,000 you will be responsible for the remaining monthly out-of-pocket costs. Patient must have private insurance with coverage of NYVEPRIA. This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs. You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required. You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs. This program is not valid where prohibited by law. This program cannot be combined with any other savings, free trial or similar offer for the specified prescription. **Co-pay card will be accepted only at participating pharmacies. This program is not health insurance.** This program is good only in the U.S. and Puerto Rico. This program is limited to 1 per person during this offering period and is not transferable. No other purchase is necessary. Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this program without notice. This program may not be available to patients in all states. For more information about Pfizer, visit www.pfizer.com. For more information about the Pfizer Oncology Together Co-Pay Savings Program for Injectables, visit pfizeroncologytogether.com, call 1-877-744-5675, or write to Pfizer Oncology Together Co-Pay Savings Program for Injectables, P.O. Box 220366, Charlotte, NC 28222. Program terms and offer will expire at the end of each calendar year. Before the calendar year ends, you will receive information and eligibility requirements for continued participation.

Please see Important Safety Information and Indication on pages 13-16, and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.



ARE ANY OTHER PATIENT SUPPORT RESOURCES AVAILABLE?

At Pfizer Oncology Together, our Care Champions, who have social work experience, can provide you resources that may help with some of your day-to-day challenges*:



Connections to emotional support resources

Connections to independent organizations that help eligible patients find free rides and lodging for treatment-related appointments



Educational information about physical and mental health, nutrition, and NYVEPRIA

Information to help you prepare for leaving or returning to work



*Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at [NYVEPRIA.com](https://www.nyvepria.com).

INJECTION
Nyvepria™
pegfilgrastim-apgf


IS THERE A DIGITAL RESOURCE THAT CAN HELP ME KEEP TRACK OF MY CANCER CARE?

A free app designed to help manage life with cancer

Whether you're living with cancer or want to support someone who is, **LivingWith™**, a free app developed by Pfizer Oncology, may help you stay connected and organized, all in one place.

Visit [ThisIsLivingWithCancer.com](https://www.thisislivingwithcancer.com) to learn more. Available in English and Spanish. Download **LivingWith** for free.



The free resources offered through **This Is Living With Cancer™** and **LivingWith™** are available to anyone living with cancer and their loved ones, and are not specific to NYVEPRIA.

App Store is a service mark of Apple Inc., registered in the U.S. and other countries. Google Play and the Google Play logo are trademarks of Google LLC.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at [NYVEPRIA.com](https://www.nyvepria.com).





INDICATION

NYVEPRIA is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count in people with certain types of cancer (non-myeloid) who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

IMPORTANT SAFETY INFORMATION

Do not take NYVEPRIA if you have had a serious allergic reaction to pegfilgrastim products or filgrastim products.

Before you receive NYVEPRIA, tell your healthcare provider about all of your medical conditions, including if you:

- Have a sickle cell disorder
- Have kidney problems
- Are pregnant or plan to become pregnant. It is not known if NYVEPRIA will harm your unborn baby
- Are breastfeeding or plan to breastfeed. It is not known if NYVEPRIA passes into your breast milk

Important Safety Information continued on next page.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


IMPORTANT SAFETY INFORMATION (continued)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NYVEPRIA may cause serious side effects, including:

- **Spleen rupture.** Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or your left shoulder
- **A serious lung problem called Acute Respiratory Distress Syndrome (ARDS).** Call your healthcare provider or get emergency help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing
- **Serious allergic reactions.** NYVEPRIA can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using NYVEPRIA and call your healthcare provider or get emergency medical help right away
- **Sickle cell crises.** You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive NYVEPRIA. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing
- **Kidney injury (glomerulonephritis).** NYVEPRIA can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual
- **Increased white blood cell count (leukocytosis).** Your healthcare provider will check your blood during treatment with NYVEPRIA

Important Safety Information continued on next page.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


IMPORTANT SAFETY INFORMATION (continued)

NYVEPRIA may cause serious side effects, including (continued):

- **Decreased platelet count (thrombocytopenia).** Your healthcare provider will check your blood during treatment with NYVEPRIA. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with NYVEPRIA. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot
- **Capillary Leak Syndrome.** NYVEPRIA can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
 - swelling or puffiness and are urinating less than usual
 - trouble breathing
 - swelling of your stomach area (abdomen) and feeling of fullness
 - dizziness or feeling faint
 - a general feeling of tiredness
- **Myelodysplastic syndrome and acute myeloid leukemia.** If you have breast cancer or lung cancer, when NYVEPRIA is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms of MDS and AML may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with NYVEPRIA
- **Inflammation of the aorta (aortitis).** Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received pegfilgrastim products. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms

Important Safety Information continued on next page.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf


IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of NYVEPRIA are pain in the bones, arms, and legs.

These are not all the possible side effects of NYVEPRIA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at **1-800-FDA-1088**.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

Please see Important Safety Information and Indication on pages 13-16 and full Prescribing Information, Patient Information, and Instructions for Use available at NYVEPRIA.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf




INJECTION
Nyvepria™
pegfilgrastim-apgf




NYVEPRIA is a trademark of Pfizer Inc.
Neulasta® (pegfilgrastim) is a registered trademark of Amgen Inc.

PP-PEG-USA-0174 © 2022 Pfizer Inc. All rights reserved. Rx only. June 2022

